Iovance BiotherapeuticsIOVA
About: Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Employees: 557
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
80% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 9 (+4) [Q3]
79% more call options, than puts
Call options by funds: $44.1M | Put options by funds: $24.7M
29% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 83
17% more capital invested
Capital invested by funds: $1.89B [Q2] → $2.2B (+$316M) [Q3]
4% less funds holding
Funds holding: 294 [Q2] → 282 (-12) [Q3]
6.86% less ownership
Funds ownership: 84.11% [Q2] → 77.25% (-6.86%) [Q3]
24% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 51
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 80 / 385 met price target | 334%upside $32 | Buy Reiterated | 6 Nov 2024 |
UBS David Dai 18% 1-year accuracy 2 / 11 met price target | 130%upside $17 | Buy Initiated | 24 Oct 2024 |
Financial journalist opinion
Based on 9 articles about IOVA published over the past 30 days
